O. Elibol et al., THE DETERMINATION OF ADDITIVE EFFECT AND INTRAOCULAR-PRESSURE LOWERING EFFECTS OF 0.05-PERCENT BROMOCRIPTINE AND 0.25-PERCENT TIMOLOL, International ophtalmology, 20(1-3), 1997, pp. 53-55
It has been confirmed that topically applied bromocriptine has a satis
factory intraocular pressure (IOP) lowering effect without serious ocu
lar or systemic side effects. We compared the IOP lowering effects of
0.05% bromocriptine and 0.25% timolol and determined whether they have
an additive effect in lowering IOP in normal volunteers. In a double-
blind, randomised, prospective, single-dose study, we measured IOP in
24 ocular normotensive subjects before (baseline) and 2, 4 and 6 hours
after topical instillation of the following drugs: timolol and bromoc
riptine alone (n : 14), timolol + bromocriptine, timolol + placebo, br
omocriptine + placebo (n : 10). Both bromocriptine and timolol have a
significant IOP lowering effect (P < 0.01) compared with the baseline
value during the study period. There were no significant differences i
n IOP lowering effect between timolol and bromocriptine at 2 and 4 hou
rs (P > 0.05), but timolol was more efficacious than bromocriptine at
6 hours (p < 0.05). An additive effect in lowering IOP was not found.
Although timolol and bromocriptine have no additive effect in lowering
IOP, topically applied bromocriptine may be used in the treatment of
glaucoma.